I'll begin my coverage of the #ASCO21 Annual meeting I have been attending virtually with comments and tweets from the Monday June 7th Gyneocologic Cancer Oral Abstract session.
Not all the studies report were "blockbuster", not all provided results the researchers expected but in each and every one of them we - researchers, clinicians and patients learned something.
Here is my tweet summary:
OVARIAN CANCER
PDL1 inhibitor / Neoadjuvant chemo plus Bevacizumab
Oral Abstract Session
— Dee Sparacio (@womenofteal) June 7, 2021
Gynecologic Cancer #ASCO21 #gyncsm #OncoAlert
Isabelle Laure Ray-Coquard, @CoquardRay
PDL-1 inhibitor w/ NACT for adv #ovca + Bev
Small increase of ORR in CT+P Arm pic.twitter.com/SADhYogHTG
GINECO neoadj chemo +/- pembro:
— Erika Hamilton, MD (@ErikaHamilton9) June 7, 2021
💢rate of complete debulking 70% -> 73.8%. (Met primary endpoint but control arm performed better than expected)
💢ORR 62% vs. 73%
📛PFS longer without pembro 20.8 no (vs. 19.3 w/pembro) #gyncsm @OncoAlert pic.twitter.com/w04zccqONv
GEM vaccine (Gemogenovatucel)
Oral Abstract Session
— Dee Sparacio (@womenofteal) June 7, 2021
Gynecologic Cancer #ASCO21 #gyncsm #OncoAlert@rodrocconi novel GEM vaccine vs placebo every 4 weeks maintenance, 91 patients
Gem well tolerated.
Benefit for Homologous Recombination proficient patients pic.twitter.com/eK4OIdt7wi
While the GEM tumor vaccine did not improve RFS in the all comers population, women with homologous recombination proficient tumors had RFS and OS benefit from this therapy - will be interesting to see larger studies of this agent in the selected population #ASCO21 #gyncsm pic.twitter.com/CkSlw7Vdaa
— Shannon Westin (@ShannonWestin) June 7, 2021
Bevacizumab 15 months vs 30 months
Oral Abstract Session
— Dee Sparacio (@womenofteal) June 7, 2021
Gynecologic Cancer #ASCO21 #gyncsm #OncoAlert
Pfisterer
Bev for 15 months vs 30 months for #ovca, 900 patients
PFS no difference between treatment arms ( 24 months vs 26 months)
15 mo remains STD pic.twitter.com/nSW4i3FuzQ
It's an #ASCO21 theme in Gyn Cancers - MORE is NOT always better! The additional months of bevacizumab DID NOT improve PFS in advanced #ovariancancer. There was no diff based on residual disease and adverse events were similar b/w both arms. #gyncsm pic.twitter.com/89D7oDMVDc
— Shannon Westin (@ShannonWestin) June 7, 2021
Agent given to highlight tumors with overexpression of folate receptor Alpha during surgery
Oral Ab
— Dee Sparacio (@womenofteal) June 7, 2021
Gynecologic Cancer #ASCO21 #gyncsm #OncoAlert
Janos Laszlo Tanyi, @Janos
Pafolacianine Sodium injection (OTL38) agent overexpression of folate receptor alpha shows under fluorescence imaging
Demonstrated higher rate of detection and removal of lesions
R0 surgery is goal pic.twitter.com/mNAe9LMknA
Mirvetuximab plus Bev for recurrent OC
Oral Abstract Session
— Dee Sparacio (@womenofteal) June 7, 2021
Gynecologic Cancer #ASCO21 #gyncsm #OncoAlert
David M. O'Malley Mirvetuximab +Bev in recurrent #ovca
11.8 month mDOR , 10.6 mo PFS
Combo promising for high FR alpha patients pic.twitter.com/o5TXAUA2i2
#ASCO21 #gyncsm @omalleygynonc presents mirvetuximab plus bevacizumab (phase 1) in rec on a. I agree: compelling results; sufficient to move forward. While no new safety signals, the tox remains significant: diarrhea (68%) blurred vision (63%) fatigue (58%) severe HTN (13%) pic.twitter.com/GkYVW0kesx
— Don S. Dizon MD 🇬🇺 (@drdonsdizon) June 7, 2021
Adavosertib w and w/out Olaparib
Oral Abstract Session
— Dee Sparacio (@womenofteal) June 7, 2021
Gynecologic Cancer #ASCO21 #gyncsm #OncoAlert @ShannonWestin EFFORT: adavosertib (Wee1) alone and in combo w/ olarparib in rec OC
80patients,
AD alone and combo -efficacy in PARP resistant OC pic.twitter.com/1TENLsm2dx
Endometrial Cancer
Intensive Follow-up after endometrial cancer treatment
Endometrial Cancer
— Dee Sparacio (@womenofteal) June 7, 2021
Paolo Zola TOTEM
Oral Abstract Session
Gynecologic Cancer #ASCO21 #gyncsm #OncoAlert
1884 enrolled
Intensive follow-up in endometrial cancer does not improve OS. pic.twitter.com/zSnIsksKaG
mTOR inhibitor and Anastrozole
Endometrial Cancer
— Dee Sparacio (@womenofteal) June 7, 2021
Oral Abstract Session
Gynecologic Cancer #ASCO21 #gyncsm #OncoAlert
Heudel VICTORIA
Vistusertib (mTOR inhibitor) + Anastrozole
PFS 5.2 mo combo vs 1.9 mo pic.twitter.com/lEkPQQLyXb
Pertuzumab and Trastuzumab in uterine cancer patients with ERBB2/ERBB3
Oral Abstract Session
— Dee Sparacio (@womenofteal) June 7, 2021
Gynecologic Cancer #ASCO21 #gyncsm #OncoAlert #TAPUR
Pertuzumab +Trastuzumab in patients w uterine cancer & overexpression,mutation ,amplification
ERBB2/ERBB3 28 patients
PFS 28.1 mo
Anti-tumor activity seen with combo pic.twitter.com/KqlJfuEAur
Over the next few days I'll be sharing tweets from the disparity, plenary ( cervical cancer study) and poster sessions. Stay tuned.
Dee
Every Day is a Blessing!
No comments:
Post a Comment